

CV for Ove Andersen

Name: Ove Andersen

Born: September 26th, 1959, Kolding, Denmark

Nationality: Danish

E-mail: ove.andersen.privat@gmail.com

Work: Clinical Research Centre, Amager and Hvidovre Hospital,
Kettegaard Allé 30, DK-2650 Hvidovre, Denmark

Phone: +45 3632 3335 **Mobile** +45 2933 3262



Summary

Chief Physician in internal medicine, infectious diseases and Clinical Professor at Copenhagen University. I am Head of the Clinical Research Centre at Amager and Hvidovre Hospital and have led the strategic development of the department from 7 to 55 employees. I also hold the position of Research Director at the Hospital. I am responsible for the strategic development of research at the hospital, identification and establishment of innovative projects that carry patient benefit and thereby relevance for health and society, and for creating knowledge and infrastructure to secure research implementation.

I have more than 20 years of experience as research leader of different research groups. Currently, I am head of three interdisciplinary projects concerning biomarkers, Biological ageing and patient involvement. The projects Optimed "Optimized Senior Patient Program", and "Biological Ageing in Acutely admitted patients", consist of a staff of more than 30 scientific senior researchers, postdocs, PhD students and master students.

In September 2016, I defended my doctoral dissertation entitled: " A characterization of low-grade inflammation and metabolic complications in HIV-infected patients". This work represents a model of biological aging, and the knowledge gained from this work has been a keystone and is used in my present scientific focus on biological aging and estimation and prediction of frailty in the acutely admitted patients.

I am (co-)author of more than 130 peer reviewed scientific publications (31 papers as first author or split first author and 32 as senior author) and have an H-index of 28. I have been principal investigator of numerous clinical trials within the field of infectious diseases and acute medicine.

As inventor of 4 international patents Ove Andersen does also have long experience in knowledge and technology transfer as well as managing implementation of technologies into clinical practice. The first biomarker patent on SAP as treatment modality for influenza, was licensed out in 2003. The second biomarker patent on suPAR reached the market in 2009 (*virogates.com*); the third patent (*oracain.com*) based on bupivacaine lozenge to mucositis pain management has reached proof-of-concept and the IP rights was sold in April 2014 (Moberg Pharma); where a Phase III study is about to be launched with funds from Eurostar. The fourth is a dividable cryotube invented for the purpose of optimizing usability of biomarkers. The cryotubes won in 2015 the FINAT label award in the category Pharma / Medical and overall the most innovative Product in Europe.

Areas of research

Within my research program, research lines with *bio-medical focus* and a *socio- implementation focus* and a *physio-rehab focus* are performed.

Bio-medical focussed research line

- Biomarkers of biological aging, chronic inflammation and nutritional risk.
- Untangling the underlying mechanisms of the biological ageing, inflammation and sarcopenia and organ dysfunction.
- Prevention and treatment of physical dependence in frail patients.
- Multimorbidity and polypharmacy.

Socio-implementation focussed research line

- Barriers and facilitators for implementation of screening tools in the Emergency Department and physical activity in elderly persons.
- Knowledge transfer across specialties and sectors.
- Communication and patient involvement.

Physio-rehab focussed research line

- Evaluation of the effect of strength training in elderly persons.
- Impairment and function.
- Development and validation of strength and fatigue resistance measurements, and reaction time tests in elderly persons and geriatric patients.

Academic degrees

2017-	Clinical Professor in Infectious Diseases at Copenhagen University
2016	Doctoral Dissertation at Copenhagen University
2011-2017	Associate Clinical Professor at University of Copenhagen
2004-2009	Associate Research Professor at University of Copenhagen
2003	Specialist in infectious diseases
1999	Specialist in internal medicine
1992	Ph.D. in immunology, at University of Odense, Denmark
1986	Medical doctor (MD) at University of Odense, Denmark

Positions

2015-2016	Appointed as Deputy Director at Amager and Hvidovre Hospital 6 months in addition to my appointment as Research Director and Head of CRC
2003-	Research Director at Amager and Hvidovre Hospital
2003-	Head of Clinical Research Centre and Consultant in infectious diseases at Amager and Hvidovre Hospital
1998-2003	Resident and Interim Consultant, Department of Infectious Diseases, Amager and Hvidovre Hospital, Denmark
1996-1998	Resident, Department of Medicine, Odense University Hospital, Denmark

- 1992-1995 Resident at various departments of medicine, Odense University Hospital, Denmark (infectious diseases, endocrinology, lung diseases)
- 1988-1991 Research fellow at the Institute of Medical Microbiology, Odense University, Denmark
- 1986-1987 Resident at surgical departments, Sønderborg Hospital (orthopedic), Svendborg Hospital (gastroenterological) and Odense University Hospital (cardiac thoracic)

Research management and administration

Institutional research leader: Research Director at Amager and Hvidovre University Hospital responsible for research administration, strategy development, Head of Clinical Research Centre with more than 13 years of experience in leadership and development of an organization with more than half of the budget based on external funding.

My leadership and the management of Clinical Research Centre has been rated and evaluated as one of the best in the *employee satisfaction survey*, performed every second year at the hospital and among the hospitals in the Capital Region of Denmark.

In 2005 as my first task as Research director I introduced the research administration program PURE together with Atira, as a pilot project in Hvidovre Hospital and later in all the hospitals in the Capital Region. In 2008 CURIS was introduced to Copenhagen University based on the same platform as PURE.

I have been a board member in Danish Association of Research Managers and Administrators (DARMA) and arranged courses for research administrators and managers. Based on this, the strategic research management program in the Capital Region of Denmark has been developed.

Supervisor

Principal supervisor for 17 PhD students (10 defended, 2 expected to submit winter 2018 and 5 ongoing) at the Graduate School of Health and Medical Sciences, Copenhagen University. Project supervisor for 6 PhD Students (2 defended, 4 ongoing). Supervisor for more than 20 bachelor and master students (3 ongoing). Evaluator of 6 PhD thesis.

Principal supervisor

MD, Kristian Kofoed; Measuring and combining multiple diagnostic and prognostic sepsis biomarkers (defended April 2008)

MD, Birgitte Rønde Hansen; Metabolic and morphologic abnormalities in HIV infection and growth hormone as therapeutic option (defended April 2009)

M.Sc.(Statistician) Janne Petersen; Classification criteria of syndromes by latent variable models.(defended March 2010)

M.Sc.(Biol) Anne Langkilde; Inflammation in HIV-infected Patients - Effects of Fat Mass, Lean Mass and Lipodystrophy (defended December 2013)

M.Sc.(Pharm) Charlotte Trelidal; Bupivacaine and Sjögren Syndrome/ Burning Mouth (defended 2 March 2015)

MD, Henrik Hedegaard Klausen; Assessing biological aging advancement in acutely admitted older medical patients (defended December 2017)

M.Sc.(Pharm) Stine Mogensen; Bupivacaine lozenge for alleviation of oral mucositis pain (defended October 2017)

MD, Thomas Haupt; Prognostic value and pathophysiological role of suPAR in low and High-risk populations (defended November 2017)

M.Sc.(Nurse) Ann Pia Søe Lytken Jensen; Nutritional care to patients with lower extremity amputation (defended January 2018)

M.Sc. (Biol) Line Jee Hartmann Rasmussen.

Clinical prognostication with the Biomarker suPAR (defended June 2018)

M.Sc.(Pharm) Line Due Christensen. Biological Aging: Identification of drugs as risk factors. (January 2014-expected November 2018)

M.Sc.(Physical Ther) Helle Gybel Juul Larsen. Epidemiological strategies for adapting Disease Management Programs to older persons with multimorbidity. (December 2014-expected November 2018)

M.Sc.(Pharm) Morten Baltzer Houllind. Optimization of drug prescribing to acutely hospitalized elderly patients (December 2016-

M.Sc. (Biol) Juliette Tavenier Mechanisms and biomarkers of biological ageing in acutely ill and healthy elderly (July 2017-)

M.Sc.(Nutrition) Aino Leegaard Andersen. Development and trial of a transitional and multimodal nutritional intervention for acutely admitted old medical patients. (September 2017-)

M.Sc.(Nurse) Ditte Maria Sivertsen. Implementation of an alcohol screening and brief intervention: A Cross continuum of targeted efforts (June 2018-)

M.Sc.(Nurse) Pia Fabricius (apply Sep 2018)

Project scientific supervisor

M.Sc.(Biol) Christian Kjærulff Mathiesen; Study of protective immune responses against hepatitis C virus (defended August 2014)

M.Sc.(Physical Ther) Ann-Christine Bodilsen; Acute admittance of older medical patients; identification of patients at risk. (defended October 2015)

MD, Lars Lindberg; Optimized Surveillance in Hereditary Colorectal Cancer - synchronous, metachronous and interval cancers, adherence, outcome and effectiveness of surveillance. (June 2014-August 2018)

MD Peter Vadim Polzik Necrotizing soft-tissue infections (NSTI) and Biomarkers (September 2015-September 2018)

Anthropologist, Signe Lindgård Andersen; How the concept of FTS travels in the global encounter between Danish and Chinese health professionals at Amager and Hvidovre hospital. (September 2015-)

M.Sc.(Nurse) Trine Schifter Larsen; Sleep pattern in elderly patients under hospitalization and rehabilitation-from the patients point of view. (October 2016-)

Evaluator

2016 Yolandi Breet PhD, North West University Potchefstroom, South Africa

2015 Shani Botha PhD, North West University Potchefstroom, South Africa

2013 Mikkel Brabrand PhD, Odense University

2010	Marianne Mikkelsen PhD, University of Copenhagen
2007	Stine Johansen PhD, Aarhus University
2004	Lars Andresen PhD, University of Copenhagen
1993-1999	Appointed Evaluator in Molecular Biology at the Science Faculties

Lecturing Pre graduate

2015-	Acute medical patients 6 sem. Medical students, Copenhagen University
2006-2009	Lecturing in Clinical Pharmacology and Biostatistics Dept. of Pharmacology and Pharmacotherapy, Pharma
2004-2009	Immunology 5 sem. SAU Immunology (17h/sem)
2002-2004	Lecturing in GCP and RCT for Nurses at Hvidovre Hospital
1998-2003	Clinical tutoring for 7.-8. sem Med. Stud. Hvidovre Hospital
1993-2000	Lectures in immunodeficiency at the school of Nurse education, Odense (8h/sem)
1993-1997	Lectures in immunology and rheumatology at the School of Physiotherapy Odense. 32 hours/sem
1988–1992	Medical microbiology at 2. part of medical study topics: Obligatory course in <ol style="list-style-type: none"> 1.1 Viro/immunology, 15 hours/sem 1.2 Mycology, 3 hours/sem 2. Lecturing in mycology, 1 hour/sem

Post graduate

2010-	Lecture in Research process from idea over patent to implementation and Course leader 3 days every 1.5 year DARMA (Danish Association for Research Managers and Administrators)
2004-2005	Lectures in Virology for specialists in Dermatology
1993-	Lectures at Clinical departments all over Denmark in topics within Virology, HIV, SIRS, Infections, Immunology Nutrition and biomarkers

Membership of Board and Steering Committee

2016-	Member of the advisory board for employers of Ms.c. University of Copenhagen
2014-	Chair of board: Executive Committee of Research, Amager and Hvidovre University Hospital
2014-	Scientific Clinical Advisor in Moberg Pharma
2014-	Inventor, Board member and CTO in 1CryoBio Aps
2012-	Member of the Strategic Research Advisory Board, Capital Region of Denmark
2011-2015	Head of the Danish National Register of Hereditary Colon Cancer (HNPC)
2011-	Inventor and Chair of Board in Oracain II Aps
2010-2012	Member of the EU advisory board in the Capital Region of Denmark
2009-2011	Board member in Danish Association of Research Managers and Administrators
2007-2011	Member of the Strategic Research board in the Capital Region of Denmark
2006-2009	Technology Ambassador at the TecTrans Unit, Capital Region of Denmark
2005-	Chair of board: The Research Council, Amager and Hvidovre Hospital

- 2003- Chair of and board-member of 10+ steering committees within research, research strategy and administration. Ex. "Info-65 på tværs" implementation of a screening tool in Emergency Department, TREAT a screening tool for infections in Emergency Department and "Tværscom" – patient related communication across sectors (from hospital to municipalities)
- 2003-2007 Member of the Research council in the Capital Region of Denmark
- 2003-2005 Member of The Research Council, Amager and Hvidovre Hospital
- 2003-2005 Member of the transfusion medical board under the Danish Health Authority
- 1999-2013 Inventor and Board member of Profylakse Aps

Selected International Collaborators:

Dr Graeme Moyle, Director of HIV Research Strategy and Associate Specialist in HIV Medicine at the Chelsea and Westminster Hospital in London, United Kingdom. (HIV, Immunology)

Dr Jonathan F Bean, Spaulding Rehabilitation Hospital, Ass. Prof. Harvard Clinical and translational Science Center, Boston, US. (Physical training, frailty, biological ageing)

Professor Neil I. Ward, Chairmain of the professional Training and Careers Committee at the University of Surrey, United Kingdom (malnutrition, micro-nutrients, tracers)

Dr Sue Green, PHD, Associated Professor, University of Southampton, United Kingdom. (undernutrition in elderly)

Professor Simon Conroy EUGMS emergency care of older people special interest group chair Geriatrician, University Hospitals of Leicester & Honorary Professor, University of Leicester United Kingdom (Geriatrics in Emergency Departments)

Prof Johannes van Rooyen, DSc (Physiology) Subject Chair: Physiology
School of Physiology, Nutrition and Consumer Sciences Faculty of Health Sciences NWU,
Potchefstroom Campus Potchefstroom, South Africa (Biomarkers in lifestyle diseases)

Publications

*The ten selected publications for the professorship are marked in yellow (2006-2016).

2016

117. **Absorption of bupivacaine after administration of a lozenge as topical treatment for pain from oral mucositis**
Mogensen S, Sverrisdóttir E, Sveindóttir K, Trelldal C, Jensen K, Jensen AB, Kristensen CA, Jacobsen J, Kreilgaard M, Petersen J, Andersen, O. 2016 I : Basic and Clinical pharmacology and toxicology (E-pub)
116. **Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomised placebo controlled study**
Lindboe JB, Langkilde A, Eugen-Olsen J, Hansen BR, Haupt TH, Petersen J, Andersen O 2016 I : Infectious diseases : 48, 11
115. **No risk of aspiration after Administration of new bupivacaine lozenge to healthy subjects and head and neck cancer patients with oral mucositis - A pilot study**
Mogensen, S., Sveinsdóttir, K., Trelldal, C., Jensen, K., Nygård, A., Ali, M. K., Jensen, F. K., Kristensen, C. A., Petersen, J. & Andersen, O. okt. 2016 I: Journal of International Research in Medical and Pharmaceutical Sciences. s. 2395-4485
114. **A characterization of low-grade inflammation and metabolic complications in HIV-infected patients**
Andersen, O. sep. 2016. Doctoral Dissertation, Danish Medical Bulletin.
113. **Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study**
Rasmussen, L. J. H., Ladelund, S., Haupt, T. H., Ellekilde, G., Poulsen, J. H., Iversen, K., Eugen-Olsen, J., Andersen, O. 2016 I : Emergency medicine journal : EMJ. 33
112. **A novel lozenge containing bupivacaine as tropical alleviation of oral mucositis pain in patients with head and neck cancer: a pilot study**
Mogensen, S., Trelldal, C., Sveinsdóttir, K., Jensen, K., Kristensen, C. A., Mogensen, T., Petersen, J. & Andersen, O. sep. 2016 I : Pain Reports . 1, 3, s. 1-5
111. **Effect of a local anesthetic lozenge in the treatment of burning mouth syndrome.**
Trelldal C, Jacobsen CB, Mogensen S, Rasmussen M, Jacobsen J, Petersen J, Pedersen AMP, Andersen O. 2016 I : Oral Diseases. 22, 2, s. 123-131
110. **The effect of protein intake and resistance training on muscle mass in acutely ill old medical patients - a randomized controlled trial.**
Buhl SF, Andersen AL, Andersen JR, Andersen O, Jensen J-EB, Rasmussen AML, Pedersen MM, Damkjær L, Gilkes H and Petersen J. Clinical nutrition. 35:59-66.
109. **Prediction of mobility limitations after hospitalization in older medical patients by simple evaluation of physical performance at admission to the**

Emergency Department. Simple measures of physical performance predict mobility limitations in older medical patients.

Bodilsen A C, Klausen H H, Petersen J, Beyer N, Andersen O, Jørgensen L M, Juul-Larsen H G, Bandholm T. PLOS One. 11, 5

108. **Plasma stromal cell-derived factor-1 α (SDF-1 α): A marker of disease burden in patients with atrial fibrillation.**
Li D, Bjørnager L, Langkilde A, Andersen O, Jøns C, Agner B, Dixen U, Landex NL. 2016 I : Scandinavian cardiovascular journal : SCJ. 50, 1, s. 36-41

2015

107. **Feasibility of progressive sit.to.stand training among older hospitalized patients**
Pedersen, M. M., Petersen, J., Bean, J. F., Damkjaer, L., Juul-Larsen, H. G., Andersen, O. Beyer, N., Bandholm, T. 2015 I : PeerJ. 3
106. **Letter to the Editor: Genetic polymorphism and soluble urokinase plasminogen receptor regulation**
Rasmussen, L. J. H., Haupt, T. H., Andersen, O., Eugen-Olsen, J. 2015 I : FASEB Journal. 29,12
105. **T-lymphocyte subset dynamics in well-treated HIV-infected men during a bout of exhausting exercise**
Dirksen, C., Hansen, B. R., Kolte, L., Haugaard, S. B. & Andersen, O. dec. 2015 I: Infectious diseases (London, England). 47, 12, s. 919-923
104. **Immunosenescence of the CD8(+) T cell compartment is associated with HIV-infection, but only weakly reflects age-related processes of adipose tissue, metabolism, and muscle in antiretroviral therapy-treated HIV-infected patients**
Tavenier, J., Langkilde, A., Haupt, T. H., Henriksen, J. H., Jensen, F. K., Petersen, J. & Andersen, O. nov. 2015 I : B M C Immunology. 16, 72, s. 1-14
103. **Leptin, IL-6, and suPAR reflect distinct inflammatory processes of adiposity, lipodystrophy and low muscle mass in HIV-infected Patients and Controls.**
Langkilde A, Petersen J, Henriksen JH, Jensen FK, Gerstoft J, Eugen-Olsen J, Andersen O. *Immunity & Aging*. 12
102. **Reply, Letter to Editor - Combined intervention of protein supplementation and resistance training in medical patients.** Buhl SF, Andersen AL, Andersen JR, Andersen O, Jensen, J-EB, Rasmussen AML, Pedersen MM, Damkjær L, Gilkes H, Petersen J.
101. **Anaysis of medical short-term admissions of elderly patients with focus on alternatives to hospitalization**
Hermansen S, Ellekilde G, Rytter L, Sales Y, Kønig KB, Andersen A, Petersen L, Andersen O. Ugeskrift for laeger. 2015, vol. 177, nr23

100. **Assessment of in situ adipose tissue inflammation by microdialysis**
Langkilde A, Andersen O, Henriksen JH, Langberg H, Petersen J, and Eugen-Olsen J. 2015, Clinical physiology and functional imaging. 35(2) 110-19
99. **Feasibility and inter-rater reliability of physical performance measures in acutely admitted older medical patients**
Bodilsen AC, Juul-Larsen HG, Petersen J, Beyer N, Andersen O, Bandholm T 2015 PLOS ONE 10(2) e0118248
98. **Indførelse af suPAR som ny prognostisk biomarkør i klinisk rutine**
Eugen-Olsen, J., Skottrup, P. D., Jee Hartmann Rasmussen, L., Ladelund, S., Andersen, O. & Poulsen, J. H. 2015 I : DSKB-Nyt. 2 Juli, s. 24-26
97. **Nutritional risk in acutely admitted older medical patients**
Lawson-Smith L, Petersen J, Jensen APS, Sivertsen DM, Pedersen MM, Ellekilde G, Lindhardt T, Andersen O. American Journal Of Food And Nutrition. 3, 3, s. 84-89

2014

96. **Association of markers of bacterial translocation with immune activation in decompensated cirrhosis**
Mortensen C, Jensen JS, Hobolth L, Dam-Larsen S, Madsen EB, Andersen O, Møller S, Bendtsen F. 2014. European journal of gastroenterology & hepatology. 26(12) 1360-6
95. **Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat**
Andersen, O., Mogensen, S., Trelldal, C., Mogensen, T. & Pulis, S. 2 okt. 2014
94. **Cardiac and proinflammatory markers predict prognosis in cirrhosis**
Wiese S, Mortensen C, Gøtze JP, Christensen E, Andersen O, Bendtsen F, Møller S. 2014. Liver international 34(6) e19-302013
93. **Potentially inappropriate medication related to weakness in older acute medical patients**
Jensen LD, Andersen O, Hallin M, Petersen J. 2014 Int J Clin Pharm. 36(3) 570-580
92. **Bupivacaine lozenge compared with lidocaine spray as topical pharyngeal anesthetic before unsedated upper gastrointestinal endoscopy: a randomized, controlled trial**
Salale N, Trelldal C, Mogensen S, Rasmussen M, Petersen J, Andersen O, Jacobsen J. 2014. Clinical Medicine Insights: Gastroenterology. 7: 55-59
91. **Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population**
Haupt TH, Kalleose T, Ladelund S, Hartmann J, Rasmussen L, Thorball CW, Andersen O, Pisinger C, Eugen-Olsen J. 2014. Biomarker insights. 9: 91-100

2013

90. **Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score**
Lyngbæk, S., Marott, J. L., Sehestedt, T., Hansen, T. W., Olsen, M. H., Andersen, O., Linneberg, A., Haugaard, S. B., Eugen-Olsen, J., Hansen, P. R. & Jeppesen, J. 10 sep 2013 I : *International Journal of Cardiology*. 167, 6, s. 2904-11 8 s
89. **CRP and suPAR are differently related to anthropometry and subclinical organ damage**
Lyngbæk, S., Sehestedt, T., Marott, J. L., Hansen, T. W., Olsen, M. H., Andersen, O., Linneberg, A., Madsbad, S., Haugaard, S. B., Eugen-Olsen, J. & Jeppesen, J. 10 aug 2013 I : *International Journal of Cardiology*. 167, 3, s. 781-85 5 s.
88. **Low-Dose Growth Hormone for 40 Weeks Induces HIV-1-Specific T-Cell Responses in Patients on Effective Combination Antiretroviral Therapy**
Herasimtschuk, A. A., Hansen, B. R., Langkilde, A., Moyle, G. J., Andersen, O. & Imami, N. 6 aug 2013 I : *Clinical and Experimental Immunology. Supplement*. 173, 3, s. 444-453 10 s.
87. **Ældre patienter med pneumoni behandles ikke i overensstemmelse med aktuelle kliniske retningslinjer**
Lindhardt Damsgaard, T., Hedegaard Klausen, H., Christiansen, C., Lawson-Smith, L., Petersen, J. & Andersen, O. 4 feb 2013 I : *Ugeskrift for Læger*. 175, 6, s. 360
86. **Acute Hospitalization of the Older Patient: Changes in Muscle Strength and Functional Performance During Hospitalization and 30 Days After Discharge**
Bodilsen, C., Pedersen, M. M., Petersen, J., Beyer, N., Andersen, O., Lawson-Smith, L., Kehlet, H. & Bandholm, T. 2013 I : *American journal of physical medicine & rehabilitation / Association of Academic Physiatrists*. 92, 9, s. 789-796
85. **Elderly patients with community-acquired pneumonia are not treated according to current guidelines**
Lindhardt Damsgaard, T., Klausen, H. H., Christiansen, C., Lawson-Smith, L., Petersen, J. & Andersen, O. 2013 I : *Danish Medical Bulletin (Online)*. 60, 2, s. A4572
84. **Twenty-Four-Hour Mobility During Acute Hospitalization in Older Medical Patients**
Pedersen, M. M., Bodilsen, C., Petersen, J., Beyer, N., Andersen, O., Lawson-Smith, L., Kehlet, H. & Bandholm, T. 2013 I : *Journals of Gerontology. Series A: Biological Sciences & Medical Sciences*. 68, 3, s. 331-337 7 s.

2012

83. **A new method to facilitate oro-tracheal intubation of awake patients: a pilot study**
Mogensen, S., Pulis, S., Kristensen, B. B., Ravn, L., Tredal, C., Rasmussen, M., Mogensen, T. & Andersen, O. 2012 I : European Journal of Anaesthesiology
82. **Correlation of Increases in 1,25-Dihydroxyvitamin D During Vitamin D Therapy With Activation of CD4+ T Lymphocytes in HIV-1-Infected Males**
Bang, U., Kolte, L., Hitz, M., Nielsen, S. D., Schierbeck, L. L., Andersen, O., Haugaard, S. B., Mathiesen, L., Benfield, T. & Jensen, J-E. B. 2012 I : HIV Clinical Trials. 13, 3, s. 162-70 9 s.
81. **Effects of anti-tumor necrosis factor therapy on body composition and insulin sensitivity in patients with psoriasis**
Kofoed, K., Clemmensen, A., Mikkelsen, U. R., Simonsen, L., Andersen, O. & Gnia-decki, R. 2012 I : Archives of Dermatology. 148, 9, s. 1089-91 3 s.
80. **High-sensitivity C-reactive protein levels predict survival and are related to haemodynamics in alcoholic cirrhosis**
Mortensen, C., Andersen, O., Krag, A., Bendtsen, F. & Møller, S. 2012 I : European Journal of Gastroenterology and Hepatology. 24, 6, s. 619-26 8 s.
79. **Inflammation in HIV-Infected Patients: Impact of HIV, Lifestyle, Body Composition, and Demography - A Cross Sectional Cohort Study**
Langkilde, A., Petersen, J., Klausen, H. H., Henriksen, J. H., Eugen-Olsen, J. & Andersen, O. 2012 I : P L o S One. 7, 12, s. e51698
78. **New lidocaine lozenge as topical anesthesia compared to lidocaine viscous oral solution before upper gastrointestinal endoscopy**
Mogensen, S., Tredal, C., Hansen, E. F., Pulis, S., Jacobsen, J., Andersen, O. & Rasmussen, M. 2012 I : Local and Regional Anesthesia. 5, s. 17-22 6 s.
77. **Outcomes in elderly Danish citizens admitted with community-acquired pneumonia. Regional differences, in a public healthcare system**
Hedegaard Klausen, H., Petersen, J., Lindhardt, T., Bandholm, T., Hendriksen, C., Kehlet, H., Vestbo, J. & Andersen, O. 2012 I : Respiratory Medicine. 106, 12, s. 1778-1787 10 s.
76. **Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study**
Haupt, T. H., Petersen, J., Ellekilde, G., Klausen, H. H., Thorball, C. W., Eugen-Olsen, J. & Andersen, O. 2012 I : Critical Care (Online Edition). 16, 4, s. R130
75. **The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men**
Haugaard, S. B., Andersen, O., Hansen, T. W., Eugen-Olsen, J., Linneberg, A., Madsbad, S., Olsen, M. H., Jørgensen, T., Borch-Johnsen, K. & Jeppesen, J. 2012 I : Diabetic Medicine. 29, 4, s. 479-487

2011

74. **Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events**
Sehestedt, T., Lyngbæk, S., Eugen-Olsen, J., Jeppesen, J., Andersen, O., Hansen, T. g, A., Jørgensen, T., Haugaard, S. B. & Olsen, M. H. 1 maj 2011 I : *Atherosclerosis*. 216, 1, s. 237-43 7 s.
73. **Polyacrylamide Gel Treatment of Antiretroviral Therapy-induced Facial Lipoatrophy in HIV Patients**
Mansor, S., Breiting, V. B., Dahlstrøm, K., Andersen, A. B., Andersen, O. & Christensen, L. H. 27 feb 2011 I : *Aesthetic Plastic Surgery*. 35, 5, s. 709-716
72. **Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals**
Langkilde, A. A., Hansen, T. W., Ladelund, S., Linneberg, A., Andersen, O., Haugaard, S. B., Jeppesen, J. L. & Eugen-Olsen, J. 2011 I : *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 20, s. 609
71. **Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1**
Andersen, E. S., Ruhwald, M., Moessner, B., Christensen, P. B., Andersen, O., Eugen-Olsen, J. & Weis, N. 2011 I : *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*. 30, 6, s. 761-6 5 s.

2010

70. **Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population**
Eugen-Olsen, J., Andersen, O., Linneberg, A., Ladelund, S., Hansen, T. W., Langkilde, A., Petersen, J., Pielak, T., Møller, L. N., Jeppesen, J., Lyngbæk, S., Fenger, M., Olsen, M. H., Hildebrandt, P. R., Borch-Johnsen, K., Jørgensen, T. & Haugaard, S. B. 1 sep 2010 I : *Journal of Internal Medicine*. 268, 3, s. 296-308 13 s.
69. **Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: a descriptive cross-sectional study**
Bang, U. C., Shakar, S. A., Hitz, M. F., Jespersen, M. S., Andersen, O., Poulsen, S. D. & Jensen, J-E. B. 1 apr 2010 I : *Scandinavian Journal of Infectious Diseases. Supplementum*. 42, 4, s. 306-10 5 s.
68. **Exercise increases interleukin-10 levels both intraarticularly and perisynovially in patients with knee osteoarthritis: a randomized controlled trial**
Helmark, I. C., Mikkelsen, U. R., Neimann, J. D. B., Rothe, A., Petersen, M. C. H., Andersen, O., Jørgensen, H. L. & Kjaer, M. 1 jan 2010 I : *Arthritis Research & Therapy*. 12, 4, s. R126

67. **Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism**
Hansen, B. R., Haugaard, S. B., Jensen, F. K., Jensen, J. E. B., Andresen, L., Iversen, J. & Andersen, O. 2010 I : HIV Medicine. 11, 4, s. 266-75

66. **Sustained low-dose growth hormone therapy optimizes bioactive insulin-like growth factor-I level and may enhance CD4 T-cell number in HIV infection**
Andersen, O., Hansen, B. R., Troensegaard, W., Flyvbjerg, A., Madsbad, S., Ørskov, H., Nielsen, J. O., Iversen, J. & Haugaard, S. B. 2010 I : Journal of Medical Virology. 82, 2, s. 197-205 8 s.

2009

65. **Is Glycogen Synthase Kinase-3 β an Ultraconserved Kernel Enzyme?**
Fenger, M., Haugaard, S. B., Andersen, O., Madsbad, S., Werge, T. & Linneberg, A. 11 dec 2009 I : Gene Expression to Genetical Genomics

64. **Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study**
Hansen, B. R., Kolte, L., Haugaard, S. B., Dirksen, C., Jensen, F. K., Ryder, L. P., Sørensens, A. L., Flyvbjerg, A., Nielsen, S. D. & Andersen, O. 2009 I : AIDS (London, England). 23, 16, s. 2123-31 8 s.

63. **Performance of the TREAT decision support system in an environment with a low prevalence of resistant pathogens**
Kofoed, K., Zalounina, A., Andersen, O., Lisby, G., Paul, M., Leibovici, L. & Andreasen, S. 2009 I : The Journal of antimicrobial chemotherapy. 63, 2, s. 400-404 4 s.

62. **Psychological stress predicts the risk of febrile episodes in cancer patients during chemotherapy**
Pedersen, A. F., Zachariae, R., Jensen, A. B., Bovbjerg, D. H., Andersen, O. & von der Maase, H. 2009 I : Psychotherapy and psychosomatics. 78, 4, s. 258-60 2 s.

61. **The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy**
Hansen, B. R., Petersen, J., Haugaard, S. B., Madsbad, S., Obel, N., Suzuki, Y. & Andersen, O. 2009 I : HIV Medicine. 10, 6, s. 378-87 9 s.

2008

60. **Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia**
Lebech, A-M., Kristoffersen, U., Wiinberg, N., Kofoed, K., Andersen, O., Hesse, B., Petersen, C., Gerstoft, J. & Kjær, A. 2008 I : European Journal of Nuclear Medicine and Molecular Imaging. 35, 11, s. 2049-2058

59. **Epstein-Barr-virus-associeret lymfom hos en patient med colitis ulcerosa i behandling med azathioprin**
Kofoed, K., Kiszka-Kanowitz, M., Albrechtsen, J. M. & Andersen, O. 2008 I : Ugeskrift for Laeger. 170, 15, s. 1255

58. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor

Kofoed, K., Eugen-Olsen, J., Petersen, J., Larsen, K. & Andersen, O. 2008 I : European Journal of Clinical Microbiology & Infectious Diseases. 27, 5, s. 375-83 8 s.

57. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy

Andersen, O., Eugen-Olsen, J., Kofoed, K., Iversen, J. & Haugaard, S. B. 2008 I : J Med Virol. 80, 2, s. 209-16 8 s.

56. suPAR associates to glucose metabolic aberration during glucose stimulation in HIV-infected patients on HAART

Andersen, O., Eugen-Olsen, J., Kofoed, K., Iversen, J. & Haugaard, S. B. 2008 I : Journal of Infection. 57, 1, s. 55-63 8 s.

2007

55. Circulating sex hormones and gene expression of subcutaneous adipose tissue oestrogen and alpha-adrenergic receptors in HIV-lipodystrophy: implications for fat distribution

Andersen, O., Pedersen, S. B., Svenstrup, B., Hansen, B. R., Paulsen, S. K., Rathje, G. S., Richelsen, B., Nielsen, J. O., Madsbad, S., Iversen, J. & Haugaard, S. B. 2007 I : Clinical Endocrinology. 67, 2, s. 250-8 8 s.

54. Glucose production, oxidation and disposal correlate with plasma lactate levels in HIV-infected patients on HAART

Haugaard, S. B., Andersen, O., Madsbad, S., Iversen, J. & Dela, F. 2007 I : Journal of Infection. 54, 1, s. 89-97 8 s.

53. Impaired proinsulin secretion before and during oral glucose stimulation in HIV-infected patients who display fat redistribution

Haugaard, S. B., Andersen, O., Halsall, I., Iversen, J., Hales, C. N. & Madsbad, S. 2007 I : Metabolism. 56, 7, s. 939-46 7 s.

52. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study

Kofoed, K., Andersen, O., Kronborg, G., Tvede, M., Petersen, J., Eugen-Olsen, J. & Larsen, K. 2007 I : Critical Care (Print). 11, 2, s. R38 10 s.

2006

51. Development and validation of a multiplex add-on assay of biomarkers related to sepsis using xMAP technology

Kofoed, K., Vest Schneider, U., Scheel, T., Andersen, O. & Eugen-Olsen, J. 11 maj 2006 I : Clinical Chemistry (Washington, DC). 52, 7, s. 1284-93

50. **Glucose-stimulated prehepatic insulin secretion is associated with circulating alanine, triglyceride, glucagons, lactate and TNF-alfa in patients with HIV-lipodystrophy**
 Haugaard, S. B., Andersen, O., Pedersen, S. B., Dela, F., Holst, J. J., Deacon, C., Iversen, J. & Madsbad, S. 2006 I : HIV Medicine. 7, s. 163-172 10 s.
49. **Growth factors, glucose and insulin kinetics after low dose growth hormone in HIV - lipodystrophy**
 Haugaard, S. B., Andersen, O., Flyvbjerg, A., Ørskov, H., Madsbad, S. & Iversen, J. 2006 I : Journal of Infection. 52, 6, s. 389-398 10 s.
48. **Hyperproinsulinaemia in normoglycaemic lipodystrophic HIV-infected patients**
 Haugaard, S. B., Andersen, O., Hales, C. N., Halsall, I., Rosenfalck, A. M., Iversen, J. & Madsbad, S. 2006 I : European Journal of Clinical Investigation. 36, s. 436-445 10 s.
47. **Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population**
 Hansen, A. B., Lindegaard, B., Obel, N., Andersen, O., Nielsen, H. & Gerstoft, J. 2006 I: HIV Medicine. 7, 1, s. 38-45
46. **Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy**
 Haugaard, S. B., Andersen, O., Pedersen, E. S., Dela, F., Fenger, M., Richelsen, B., Madsbad, S. & Iversen, J. 2006 I : Metabolism. 55, 2, s. 175-82 8 s.

2005

45. **Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy**
 Haugaard, S. B., Andersen, O., Vølund, A., Hansen, B. R., Iversen, J., Andersen, U. B., Nielsen, J. O. & Madsbad, S. 2005 I : Clinical Endocrinology. 62, 3, s. 354-361 8 s.
44. **Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells**
 Haugaard, S. B., Andersen, O., Dela, F., Holst, J. J., Storgaard, H., Fenger, M., Iversen, J. & Madsbad, S. 2005 I : European journal of endocrinology / European Federation of Endocrine Societies. 152, 1, s. 103-112 10 s.
43. **Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy**
 Haugaard, S. B., Andersen, O., Pedersen, S. B., Dela, F., Richelsen, B., Nielsen, J. O., Madsbad, S. & Iversen, J. 2005 I : Journal of Medical Virology. 77, 1, s. 29-38 9 s.

42. **Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy**
Andersen, O., Haugaard, S. B., Holst, J. J., Deacon, C. F., Iversen, J., Andersen, U. B., Nielsen, J. O. & Madsbad, S. 2005 I : HIV Medicine. 6, 2, s. 91-8 7 s.
41. **Hypereosinofilt syndrom**
Troelsen, L. N., Boisen, L. W. & Andersen, O. 2005 I : Ugeskrift for Laeger. 167, 49, s. 4663-4 2 s.
40. **In nondiabetic, human immunodeficiency virus-infected patients with lipodystrophy, hepatic insulin extraction and posthepatic insulin clearance rate are decreased in proportion to insulin resistance**
Haugaard, S. B., Andersen, O., Hansen, B. R., Andersen, U. B., Vølund, A., Iversen, J., Nielsen, J. O. & Madsbad, S. 2005 I : Metabolism. 54, 2, s. 171-9 8 s.
39. **Plasminogen activator inhibitor type I (PAI-I) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome Implications of adipokines**
He, G., Andersen, O., Haugaard, S. B., Lihn, A. S., Pedersen, S. B., Madsbad, S. & Richelsen, B. 2005 I : European Journal of Clinical Investigation. 35, 9, s. 583-90
38. **Skeletal muscle insulin signaling defects downstream of phosphatidylinositol 3-kinase at the level of Akt are associated with impaired nonoxidative glucose disposal in HIV lipodystrophy**
Haugaard, S. B., Andersen, O., Madsbad, S., Frøsig, C., Iversen, J., Nielsen, J. O. & Wojtaszewski, J. 2005 I : Diabetes. 54, 12, s. 3474-83 10 s
37. **Skeletal muscle insulin signaling defects downstream of PI3K at the level of Akt are associated with impaired non-oxidative glucose disposal in HIV-lipodystrophy**
Haugaard, S. B., Andersen, O., Madsbad, S., Frøsig, C., Iversen, J., Nielsen, J. O. & Wojtaszewski, J. F. P. 2005 I : Diabetes. 12, 54, s. 3474-83

2004

36. **Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy**
Andersen, O., Haugaard, S. B., Hansen, B. R., Orskov, H., Andersen, U. B., Madsbad, S., Iversen, J. & Flyvbjerg, A. 2004 I : Scandinavian Journal of Infectious Diseases. 36, 11-12, s. 832-9 7 s.
35. **Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review**
Hansen, B. R., Haugaard, S. B., Iversen, J., Nielsen, J. O. & Andersen, O. 2004 I : Scandinavian Journal of Infectious Diseases. 36, 4, s. 244-53 9 s.
34. **Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of beta-cells**
Haugaard, S. B., Andersen, O., Storgaard, H., Dela, F., Holst, J. J., Iversen, J., Nielsen, J. O. & Madsbad, S. 2004 I : American Journal of Physiology: Endocrinology and Metabolism. 287, 4, s. E677-85

33. **Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic human immunodeficiency virus-infected patients**

Haugaard, S. B., Andersen, O., Hansen, B. R., Orskov, H., Andersen, U. B., Madsbad, S., Iversen, J. & Flyvbjerg, A. 2004 I : Metabolism. 53, 12, s. 1565-1573 9 s.

32. **Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study**

Andersen, O., Haugaard, S. B., Flyvbjerg, A., Andersen, U. B., Ørskov, H., Madsbad, S., Nielsen, J. O. & Iversen, J. 2004 I : European Journal of Clinical Investigation. 34, 8, s. 561-568.

2003

31. **Kontrol og behandling af hiv-associeret lipodystrofisyndrom og relaterede metaboliske komplikationer**

Hansen BR, Haugaard SB, Nielsen JO, Madsbad S, Iversen J, Andersen O. 2003. Ugeskrift for læger 165(44) 4218-20

30. **HIV lipodystrophy case definition using artificial neural network modelling**

Ioannidis, J. P. A., Trikalinos, T. A., Law, M., Carr, A. & HIV Lipodystrophy Case Definition Study Group okt. 2003 I : Antiviral therapy. 8, 5, s. 435-41 7 s.

29. **To importerede tilfælde af "West Nile fever" i Danmark**

Knudsen TB, Wilcke JTR, Andersen O. 2003. Ugeskrift for læger 165(19) 2003-4

28. **Death from the Nile crosses the Atlantic: the West Nile Fever story**

Knudsen TB, Andersen O, Kronborg G. 2003. Scandinavian Journal of Infectious Diseases 35(11-12) 820-5

27. **Hiv-associeret lipodystrofisyndrom. Diagnostik, praevalens, patogenese og metaboliske komplikationer**

Haugaard SB, Hansen BR, Madsbad S, Iversen J, Nielsen JO, Andersen O. 2003. Ugeskrift for Læger 165(44) 4215-8

26. **Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels**

Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S, Andersen O. 2003. American Journal of Physiology: Endocrinology and Metabolism 285(5) E1072-80

25. **Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function**

Andersen O, Haugaard SB, Andersen UB, Friis-Møller N, Storgaard H, Vølund A, Nielsen JO, Iversen J, Madsbad S. 2003. Metabolism 52(10) 1343-1353

24. **Prenalytical handling of samples for measurement of plasma lactate in HIV patients**
Andersen O, Haugaard SB, Jørgensen LT, Sørensen S, Nielsen JO, Madsbad S, Iversen J. 2003. Scandinavian Journal of Clinical & Laboratory Investigation 63(6) 449-54

23. **Severe acute respiratory syndrome - a new coronavirus from the Chinese dragon's lair**
Knudsen TB, Kledal TN, Andersen O, Eugen-Olsen J, Kristiansen TB. 2003. Scandinavian Journal of Immunology 58(3) 277-84

2002

22. **Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance**
Worm D, Kirk O, Andersen O, Vinten J, Gerstoft J, Katzenstein T, Nielsen H, Pedersen C. 2002. HIV Medicine 3: 239-246

2001

21. **Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies**
Horvath A, Andersen I, Junker K, Fogh-Schultz BL, Holm Nielsen E, Gizurarson S, Andersen O, Karman J, Rajnavolgyi E, Erdei A, Svehag SE. 2001. Antiviral Research 52(1) 43-53

2000

20. **Fatalt forløbende Strongyloides stercoralis-infektion hos patient uden forudgående kendt immunsuppression**
Sørensen M, Andersen O, Friis-Møller A, Kvinesdal BB. 2000. Ugeskrift for læger 162(20) 2894-5
19. **Hiv-associeret lipodystrofisyndrom (HALS)**
Andersen O, Haugaard SB, Nielsen JO. 2000. Ugeskrift for læger 162(12) 1714

1997

18. **Serum amyloid P component binds to influenza A virus haemagglutinin and inhibits the virus infection in vitro**
Andersen O, Vilsgaard Ravn K, Sørensen IJ, Jonson G, Holm Nielsen E, Svehag SE. 1997. Scandinavian Journal of Immunology 46(4) 331-7

1996

17. **Infektioner i forbindelse med epidural kateterisation**
Holt HM, Gahrn-Hansen B, Andersen SS, Andersen O, Siboni K. 1996. Ugeskrift for læger 158(31) 4403-5.

16. **Binding of complement proteins C1q and C4bp to serum amyloid P component (SAP) in solid contra liquid phase**

Sørensen IJ, Nielsen EH, Andersen O, Danielsen B, Svehag SE. 1996. Scandinavian Journal of Immunology 44(4) 401-7

15. **Isolation and characterization of porcine mannan-binding proteins of different size and ultrastructure**

Storgaard P, Nielsen EH, Andersen O, Skriver E, Mortensen H, Højrup P, Holmskov U, Svehag SE. 1996. Scandinavian Journal of Immunology 43(3) 289-96

1995

14. **Infections following epidural catheterization**

Holt MS, Andersen SS, Andersen O, Gahrn-Hansen B, Siboni K. 1995. Journal of Hospital Infection 30(4) 253-60

13. **Mannan-binding protein forms complexes with alpha-2-macroglobulin. A protein model for the interaction**

Storgaard P, Nielsen EH, Skriver E, Andersen O, Svehag SE. 1995. Scandinavian Journal of Immunology 12(3) 373-80

12. **Multiple isoforms of the human pentraxin serum amyloid P component**

Sørensen, IJ, Andersen O, Nielsen EH, Svehag SE. 1995. Int Arch Allergy Immunol 106(1) 25-31

11. **Native human serum amyloid P component is a single pentamer**

Sørensen IJ, Andersen O, Nielsen EH, Svehag SE. 1995. Scandinavian Journal of Immunology 41(3) 263-7

1994

10. **Calcium-enhanced aggregation of serum amyloid P component and its inhibition by the ligands heparin and heparan sulphate. An electron microscopic and immunoelectrophoretic study**

Nielsen EH, Sørensen IJ, Vilsgaard K, Andersen O, Svehag SE. 1994. APMIS : Acta Pathologica, Microbiologica, et Immunologica Scandinavica 102(6) 420-6

1992

9. **Biochemical and ultrastructural studies of the C-type lectin bovine conglutinin**

Andersen, O., Nielsen, E. H., Storgaard, P., Højrup, P., Friis, P., Leslie, G. & Svehag, S. E. 1 nov 1992 I : Journal of Structural Biology. 109, 3, s. 201-7 7 s.

8. **Calcium-dependent and calcium-independent signals in the conglutinin-binding assay (KgBa) for immune complexes. Influence of anti-collagen-antibodies**

Holmskov, U., Haas, H. D., Teisner, B., Andersen, O. & Jensenius, J. C. 8 apr 1992 I : Journal of Immunological Methods. 148, 1-2, s. 225-32 8 s.

7. **Purification, subunit characterization and ultrastructure of three soluble bovine lectins: conglutinin, mannose-binding protein and the pentraxin serum amyloid P-component**
Andersen, O., Friis, P., Holm Nielsen, E., Vilsgaard, K., Leslie, R. G. Q. & Svehag, S. E. 1992 I: Scandinavian Journal of Immunology. 36, 1, s. 131-41
6. **Mammalian lectins, their structure and functions. An experimental study with special emphasis on conglutinin**
Andersen, O. Dec 1992 PhD theses

1991

5. **Conglutinin exhibits a complement-dependent enhancement of the respiratory burst of phagocytes stimulated by E. coli**
Friis, P., Svehag, S. E., Andersen, O., Gahrn-Hansen, B. & Leslie, R. G. dec 1991 I : Immunology. 74, 4, s. 680-4 5 s.
4. **Conglutinin binds the HIV-1 envelope glycoprotein gp 160 and inhibits its interaction with cell membrane CD4**
Andersen, O., Sørensen, A. M., Svehag, S. E. & Fenouillet, E. jan 1991 I : Scandinavian journal of immunology. 33, 1, s. 81-8 8 s.
3. **Mammalian lectins in defence mechanisms against microorganisms**
Andersen O, Laursen SB, Svehag SE, Holmskov U & Thiel S. Invited review to Lectins Reviews 1991;1:11-51, Killpatrick, D.C., van Driessche, E & Bøg-Hansen, TC, Eds. Sigma Chemical Co., Sct. Louis, MO USA. Book Chapter

1990

2. **In vivo and in vitro antibacterial activity of conglutinin, a mammalian plasma lectin**
Friis-Christiansen, P., Thiel, S., Svehag, S. E., Dessau, R., Svendsen, P., Andersen, O., Laursen, S. B. & Jensenius, J. C. apr 1990 I : Scandinavian journal of immunology. 31, 4, s. 453-60 8 s.

1987

1. **Sundhedsbetjeningen i danske fængsler**
Andersen, O., Espensen, N., Jakobsen, E. H., Jensen, A. B., Kjaer, N. K. & Lintrup, M. 15, jun 1987 I : Ugeskrift for læger. 149, 25, s. 1701-4 4 s.

Patents

Four commercialized international patents. The first biomarker patent on SAP as treatment modality for influenza, was licensed out in 2003. The second biomarker patent on suPAR reached the market in 2009 (*virogates.com*); the third patent (oracain.com) based on bupivacaine lozenge to mucositis pain management has reached proof-of-concept and the IP rights was sold in April 2014 (Moberg Pharma); at Oracain I am in charge of scientific and clinical studies, with responsibility for management and design of trials, where a Phase III study is about to be launched with funds from Eurostar. The fourth is a divideable cryotube invented for the purpose of optimizing usability of biomarkers, where we established 1CryoBio Aps in Lucerne in February 2014 (1CryoBio.com). The first product was manufactured December 2014, and the first cryotubes have been sold. Further the cryotubes won in 2015 the FINAT label award in the category Pharma / Medical and overall the most innovative Product in Europe.

Patent 1. PHARMACEUTICAL COMPOSITION COMPRISING SERUM AMYLOID P COMPONENT FOR PROPHYLACTIC OR THERAPEUTIC TREATMENT OF VIRUS INFECTIONS AND A KIT FOR DETECTING BINDING OF COMPOSITIONS TO VIRUS COMPONENTS

The invention is based on a recombinant, stable human serum protein, the biomarker serum amyloid P component (SAP), which in preclinical studies has documented a broad antiviral effect on influenza and parainfluenza virus infections. SAP binds to the haemagglutinin of influenza virus thereby inhibiting its binding to epithelial cells in the respiratory tract. In this way the initial infection and spread of influenza A virus is inhibited/blocked. Twenty-two different influenza A virus strains as well as influenza B virus and parainfluenza virus have shown to be inhibited by SAP. Profylakse was a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark Sven-Erik Svehag, DVM, VMD, em. Professor, CEO, Ellen Holm Nielsen, DVM, DMV, em. Professor and Ove Andersen, MD, Ph.D, Research Director. Profylakse entered into License Agreement in 2003 with a company with expertise in recombinant and antiviral technology Viral Therapeutics (VTI) Inc. (to-day Vybion) a collaboration that terminated in 2010 due to lack of progress, and the Global financial crises. Profylakse's antiviral technology is protected by worldwide patents. USP 6,406,698 (2002), EP Patent 0,915,707, (2002). The original idea to the invention came from Ove Andersens research in the biomarker lectins, part of the innate immune system (ref 18).

Patent 2. METHOD AND TOOL FOR PREDICTING CANCER AND OTHER DISEASES

The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovascular disease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic syndrome and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes.

US Patent Application 20100098705. Eu Patent Application EP2115478. The invention reached the market in 2009 (*virogates.com*). SuPAR was in 2014 implemented as a routine biomarker in all acutely admitted medical patients at Hvidovre Hospital and are in progress of being implemented in other hospitals in Europe.

The original idea to the invention came from Ove Andersens research on Biomarkers in HIV (summarized in ref.114).

Patent 3. A STORAGE VESSEL AND A BREAK TOOL FOR DIVIDING SUCH VESSEL

Biomarker research has progressed significantly in the later years and the research opportunities continuously increases and the platform technologies keep improving. Consequently flexible use and storage of biomaterial at a cost effective way is needed. No cryo tubes available today, offers both such flexibility and cost effectiveness. Flexi-Quot combines the flexibility of the 1 ml. cryo tubes with the cost effectiveness of 5 ml. cryo tubes. Flexi-Quot offers both flexibility and cost effectiveness by

- being dividable in subsections,
- without thawing the sample material,
- while keeping the unused material frozen and intact, with
- less labor-intensive procedures and
- reduced need for costly freezing capacity

The invention concerns a breakable multi-specimen storage vessel. The vessel comprises a tubular container that is continuously formed and provided with break portions at predetermined positions alongside thereof. Said container is adapted to be broken into a plurality of specimens. The invention further relates to a break tool for breaking off specimens from a multi-specimen storage vessel such as a storage vessel according to the invention.

United States Patent Application 20100303688.

The invention, which is owned by Janne Petersen and Ove Andersen, was in February 2014 sold to 1CryoBio (www.1crybio.com) situated in Lucerne, Swiss.

Patent 4. PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANAESTHETIC SUCH AS BUPIVACAINE FOR LOCAL ADMINISTRATION TO THE MOUTH OR THROAT

Bupizenge, new reformulations of bupivacaine into lozenge forms. Indication 1: Topical treatment of acute oral pain caused by Oral Mucositis. Indication 2: Topical treatment of chronic oral pain in oral syndromes. Indication 3: within Odontology Indication 4: Endoscopy procedures. Phase I: Trial in Healthy individuals was completed May 2011 and demonstrated safety. Phase II: Pilot trials and randomized control trials in Mucositis and other oral indications have been performed. Oracain II Aps is a start-up Biotech company a Virtual entity Oracain led by life science professionals (CoB, CeO, Ove Andersen) and leading scientists, developing new oral pain medications based on known anesthetic compounds reformulated to suit the unmet medical need in a range of indications.

Application filed May 2011. The IP rights was sold to Moberg Pharma, Sweden in April 2014. Funding for a multicenter Phase III study as part of a "Eurostar Project" has been achieved and is to be launched in 2017.

The inventions originate from Hvidovre Hospital, Copenhagen, Denmark where Ove Andersen is co-inventor together with Torben Mogensen, Stine Mogensen, Charlotte Trelidal and Sylvia Pulis.(ref.83, 92, 95, 111, 112, 115, 117).